Literature DB >> 2289532

Endothelin is a potent constrictor of human vessels used in coronary revascularization surgery.

K B Costello1, D J Stewart, R Baffour.   

Abstract

We studied the interaction of endothelin and endothelium-derived relaxing factor (EDRF) in human saphenous veins and internal mammary arteries using isolated ring preparations. Endothelin was a more potent constrictor of human internal mammary arteries and saphenous veins than norepinephrine. The ability of acetylcholine to reverse endothelin-induced contraction was greater in the internal mammary arteries than in saphenous veins. However, nitroprusside produced similar and near-complete inhibition of endothelin precontraction in both arteries and veins. We conclude that endothelin is a potent constricting agent in human internal mammary arteries and saphenous veins in vitro. Endothelin-induced vasoconstriction is effectively inhibited by EDRF, but human saphenous veins appear to have limited capability for endothelium-dependent dilation.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2289532     DOI: 10.1016/0014-2999(90)90450-k

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  9 in total

1.  Potential role of endothelin receptor antagonists in the setting of cardiopulmonary bypass: relevance to myocardial performance.

Authors:  A Ergul; C Joffs; A C Walker; F G Spinale
Journal:  Heart Fail Rev       Date:  2001-12       Impact factor: 4.214

2.  Comparative effects of endothelin (ET-1) and U46619 on human saphenous vein and gastroepiploic artery, sources of human autologous grafts.

Authors:  D B McNamara; J T Light; R K Minkes; R M Saroyan; P Kvamme; N Rowe; W R Webb; L Fox; M D Kerstein; N L Mills
Journal:  Mol Cell Biochem       Date:  1992-11-04       Impact factor: 3.396

3.  Endothelin receptor expression and pharmacology in human saphenous vein graft.

Authors:  J J Maguire; A P Davenport
Journal:  Br J Pharmacol       Date:  1999-01       Impact factor: 8.739

4.  Evidence for heterogeneity of endothelin receptor distribution in human coronary artery.

Authors:  T Godfraind
Journal:  Br J Pharmacol       Date:  1993-11       Impact factor: 8.739

5.  ETA receptor-mediated constrictor responses to endothelin peptides in human blood vessels in vitro.

Authors:  J J Maguire; A P Davenport
Journal:  Br J Pharmacol       Date:  1995-05       Impact factor: 8.739

6.  Influence of endothelium and surgical preparation on responses of human saphenous vein and internal thoracic artery to angiotensin II.

Authors:  J E Barker; J Anderson; T Treasure; P J Piper
Journal:  Br J Clin Pharmacol       Date:  1994-07       Impact factor: 4.335

7.  Pharmacological reactivity of human epicardial coronary arteries: phasic and tonic responses to vasoconstrictor agents differentiated by nifedipine.

Authors:  A P Stork; T M Cocks
Journal:  Br J Pharmacol       Date:  1994-12       Impact factor: 8.739

8.  Interaction between endothelin and vasodilators in the human internal mammary artery.

Authors:  G W He; C Q Yang; M J Mack; T E Acuff; W H Ryan; A Starr
Journal:  Br J Clin Pharmacol       Date:  1994-12       Impact factor: 4.335

9.  Endothelin ETA and ETB mRNA and receptors expressed by smooth muscle in the human vasculature: majority of the ETA sub-type.

Authors:  A P Davenport; G O'Reilly; R E Kuc
Journal:  Br J Pharmacol       Date:  1995-03       Impact factor: 8.739

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.